Onconetix (NASDAQ:ONCO – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Institutional and Insider Ownership
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Onconetix and Editas Medicine”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Onconetix | $810,000.00 | 3.97 | -$14.03 million | $248.12 | 0.00 |
| Editas Medicine | $40.52 million | 9.91 | -$160.06 million | ($0.75) | -3.49 |
Onconetix has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Onconetix has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Onconetix and Editas Medicine, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
| Editas Medicine | 1 | 0 | 5 | 0 | 2.67 |
Editas Medicine has a consensus target price of $5.80, suggesting a potential upside of 121.80%. Given Editas Medicine’s stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Onconetix.
Profitability
This table compares Onconetix and Editas Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
| Editas Medicine | -157.32% | -196.63% | -38.17% |
Summary
Editas Medicine beats Onconetix on 9 of the 14 factors compared between the two stocks.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
